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Purpose/Objective(s): Herein, we report the results of an IRB-approved phase II trial of
VarianTrilogy/TrueBeam-based stereotactic ablative body radiotherapy (SABR) monotherapy
for low-risk prostate cancer using the Calypso® System to provide real-time electromag-
netic tracking of the prostate’s position during treatment delivery.
Materials/Methods: A total of 102 low-risk patients completed protocol treatment
between January 2007 and May 2009. A total dose of 40.0 Gy in 5 every-other-day frac-
tions of 8.0 Gy was prescribed to the planning target volume. Target setup and tracking
procedures were as follows: (1) the Calypso® System was used to achieve target setup
prior to each fraction; (2) conebeam CT imaging was then used for correction of setup error
and for assessment of target and organs-at-risk deformations; (3) after treatment delivery
was initiated, the Calypso® System then provided real-time intrafractional target tracking.
The NCI CTCAE v3.0 was used to assess urinary and rectal toxicity during treatment and
at defined follow-up time points. Biochemical response and quality of life measurements
were made at concurrent follow-up points.
Results: Urinary toxicities were most common. At 6 months, 19.6, 2.9, and 4.9% of
patients reported grades 1–2 urinary frequency, dysuria, and retention, respectively. Rec-
tal toxicities were uncommon. By 12 months, 2.9% of patients reported painless rectal
bleeding with subsequent symptom resolution without requiring invasive interventions.
Quality of life measurements demonstrated a significant decline over baseline in urinary
irritative/obstructive scores at 1 month following SABR but otherwise did not demonstrate
any difference for bowel, bladder, and sexual function scores at any other follow-up time
point. One patient suffered biochemical recurrence at 6 years following SABR.
Conclusion: At 5 years, minimum follow-up for this favorable patient cohort, prostate SABR
resulted in favorable toxicity, quality of life, and biochemical outcomes.
Keywords: prostate cancer, SABR, hypofractionation
INTRODUCTION
Stereotactic ablative body radiotherapy (SABR) is a recent external
beam radiation treatment modality in the curative management
of localized prostate cancer. What primarily distinguishes SABR
from other external beam therapies is its brief treatment schedule
of five or fewer treatment fractions to deliver a biologically effective
radiation dose to the prostate gland. Improvements in linear accel-
erator targeting and beam delivery performance have allowed for
the consideration of safely compressing conventional treatment
courses of 7–9 weeks into more abbreviated treatment schedules.
In 2013, the American Society for Radiation Oncology (ASTRO)
endorsed SABR as an appropriate alternative to other, more con-
ventional therapies for selected low- and intermediate-risk disease
patients on the basis of published clinical data supportive of its
efficacy and safety (1).
As an extremely hypofractionated therapy, SABR tests a radio-
biologic hypothesis that promotes fewer and larger fractions for
effective prostate cancer irradiation. Dose–response analyses of
disease outcomes have generally concluded that the α:β ratio for
prostate cancer may be exceptionally low, with studies reporting
estimated ratios as low as 1.5 (2–9). Caveats to this conclusion of
a low α:β ratio for prostate cancer include (1) the mathematical
assumptions made in some studies in order to allow for com-
parisons between external beam radiotherapy and brachytherapy
outcomes and (2) the lack of certainty that the linear-quadratic
model may be applied to estimating dose–response when very
large fractional doses are considered (10–12). If this conclusion is,
however, true, then prostate tumor effect may be highly sensitive
to fraction size and perhaps even more so than the late effects of
surrounding normal tissue. Therefore, the clinical implication of
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a hypofractionated treatment schedule for prostate cancer may be
improved tumor control rates while maintaining a similar bio-
logically effective dose (BED) for normal tissue late effects when
compared to conventionally fractionated regimens.
A fundamental technical demand of a prostate SABR delivery
system is the ability to respond to organ motion. Prostate move-
ment is stochastic, meaning that the gland may move without
predictability in any direction and at any time (13, 14). In HDR
brachytherapy, organ motion is accounted for by intraprostatic
placement of afterloading catheters which then move with the
gland. For external beam modalities, implanted fiducial markers
are commonly used to correct for interfractional organ motion
prior to treatment delivery through the use of on-board imaging
devices integrated into the linear accelerator platform. However,
this may be inadequate for hypofractionated therapy as intrafrac-
tional prostate motion may occur with displacements of up to 1 cm
(15–20). When a small number of large fractions are administered,
there is increased need to account for this source of localization
error in order to maintain the minimal PTV margins necessary
for SBRT and, consequently, reduce normal tissue complication
probability and increase tumor control probability (21, 22). An
optimal solution for external beam modalities is therefore a sys-
tem that couples real-time tracking of the prostate to the linear
accelerator and permits immediate corrective action to changes in
prostate position within a treatment fraction.
Varian Trilogy and TrueBeam (Varian Medical Systems, Inc.,
Palo Alto, CA, USA) are rapid output linear accelerators with an
integrated image guidance system. Briefly, each linear accelera-
tor’s platform provides image guidance by robotically extending
an opposed kilovolt x-ray source and amorphous silicon flat panel
imager tandem over the target volume. The source-imager tan-
dem then acquires planar or volumetric imaging of implanted
fiducial markers and/or the target to permit corrections of target
setup error prior to treatment. During treatment, the beam may
be stopped and imaging repeated to identify and correct intrafrac-
tional target motion. While technically possible, repeat imaging
during a treatment fraction is time-consuming and is still unlikely
to identify every instance of target excursion outside the treatment
volume. The Calypso® System (Varian Medical Systems, Inc., Palo
Alto, CA) is a real-time target tracking system that provides a more
efficient solution to the problem of intrafractional target motion.
This system consists of an electromagnetic array that can detect
the positions of signal-emitting transponders implanted in the tar-
get and provides continuous information of target position with
sub-millimeter accuracy.
This report describes toxicity, quality of life, and biochemi-
cal disease outcomes from an IRB-approved, phase II trial of
conventional linear accelerator-based SABR monotherapy in the
treatment of low-risk prostate cancer using the Calypso® System
for intrafractional real-time target tracking.
MATERIALS AND METHODS
PATIENT SELECTION
A total of 102 patients were treated from January 2007 to May 2009.
All of the following eligibility criteria were required for enrollment:
clinical stage T1c–T2a, presenting serum PSA ≤10 ng/ml, and GS
≤6. Patients with GS 7 were also eligible for enrollment if the
primary histologic score were three and if ≤25% of biopsy cores
were positive. Patients were not eligible if any of the following
medical factors were present: prostate US volume >60 cc, prior
hormonal therapy, international prostate symptom score (IPSS)
>18, history of TURP, history of colostomy, history of pelvic
radiotherapy, or history of chemotherapy. Technical ineligibility
factors included implanted metallic hip prosthetic devices and
>21 cm distance between the electromagnetic array and implanted
transponders, either of which could compromise targeting and
tracking performance of the Calypso® System.
PROTOCOL TREATMENT PLANNING
Patients underwent transponder implantation at least 5 days
before treatment planning imaging to allow for resolution of
post-implant edema. Three transponders were placed transrec-
tally under ultrasound guidance and distributed such that at least
1.5 cm spacing was achieved among them.
CT imaging was performed for volume delineation and dose
calculation. Supine patient immobilization was achieved through
use of aVac-Lok device (Medtec, Inc.,Orange City, IA,USA) placed
under the lower torso, pelvis, and thighs. The CT study set was
acquired with 1.25-mm slice thickness and without contrast.
The CTV consisted of the prostate only. The PTV was created
by a uniform 2-mm expansion of the CTV in all dimensions. The
rectum was contoured as a solid structure including all intralumi-
nal contents from the sigmoid flexure to the ischial tuberosities,
encompassing a length of roughly 15 cm. The bladder was also con-
toured as a solid structure inclusive of all contents from the dome
to the bladder neck. The femoral heads were contoured from the
level of the acetabula to just inferior to the greater trochanters. The
penile bulb was contoured electively for potent patients from its
origin just inferior to the urogenital diaphragm and then anteriorly
for 2 cm toward the corpora cavernosa.
A total dose of 40.0 Gy in five fractions was prescribed to the
PTV. This schedule was selected such that its late effects BED
would be similar to that for 86.4 Gy in 48 fractions – a conven-
tionally fractionated, dose-escalated schedule previously reported
with low rates of late genitourinary and gastrointestinal toxicities
(23). Assuming both a late effects α:β of 3 and a 5% increment
to the conventional fractionation late effects BED for calculating
the SABR late effects BED (this increment assumed on the basis
of improved intrafractional target localization with the Calyp-
so® System), we may then use the BED formalism to calculate an
equivalent SABR dose schedule:
BED = (nd)+
(
nd2
α/β
)
BEDconv late effects = (48 · 1.8)+
(
48 · 1.82
3
)
= 138.24
BEDSABR late effects = 138.24+ (138.24 · 5%) = 145.15
145.15 = (5 · dSABR)+
(
5 · (dSABR)2
3
)
dSABR ∼= 8.0 Gy
Intensity-modulated treatment planning was performed using
CMS XiO Planning System (CMS Software, Inc.; Elekta Group;
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Stockholm, Sweden). A typical treatment plan consisted of seven
or nine intensity-modulated fields arranged isocentrically in a
non-opposing, coplanar orientation. Each field consisted of 10
intensity levels. Target volume coverage acceptance parameters
included PTV40Gy ≥98% and CTV40Gy ≥100%. Organs-at-risk
(OAR) dose-volume constraints for SABR were appropriated from
conventional fractionation limits and converted for hypofraction-
ated therapy using BED calculations as above. Required OAR
constraints for protocol treatment included rectum D15 <32.7 Gy,
bladder D15 <34.9 Gy, and penile bulb mean dose<22.9 Gy. Rep-
resentative isodose distributions and dose-volume histograms are
provided in Figures 1 and 2.
PROTOCOL TREATMENT
Treatment was delivered according to an every-other-day schedule
over 10 calendar days. Patient preparation consisted of over-
the-counter laxatives the evening prior to treatment and then
NPO after midnight. This preparation regimen was also used
for planning imaging. With Calypso® tracking, an excursion
threshold of 2 mm in all dimensions (lateral, anteroposterior, and
superoinferior) was assigned. If the Calypso® System detected any
target movement beyond this limit, then the treatment beam was
immediately stopped and then resumed once the transponder
coordinates were detected within the assigned threshold. If the
beam remained interrupted for more than two continuous min-
utes, then the patient and target were realigned before completing
treatment.
ASSESSMENTS
The NCI CTCAE v3.0 was used to assess urinary and rectal toxicity
at baseline, during treatment and at the following post-treatment
points: 1, 3, 6, 9, 12, 18, 24, 36, 48, and 60 months. Toxicity out-
comes are represented as crude rates at the defined time points.
A description of the NCI urinary and rectal toxicity scales is pro-
vided in Table 1. Biochemical response determinations were made
at concurrent follow-up points. Biochemical failure was defined
as post-therapy PSA nadir +2 ng/ml. All patients completed an
expanded prostate cancer index composite (EPIC-26) question-
naire prior to treatment and again at 6, 12, 18, 24, 36, 48, and
60 months post-treatment.
FIGURE 1 | Representative isodose distributions of an SABR treatment plan.
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FIGURE 2 | Representative dose-volume histogram of an SABR treatment plan.
RESULTS
A total of 102 patients have been treated and followed for a min-
imum of 5 years. Seventy patients were diagnosed with Gleason
score 3+ 3 disease, and 32 patients were diagnosed with Glea-
son score 3+ 4 disease. Mean PSA at presentation was 7.30 ng/ml
(range, 3.42–10.0 ng/ml) for the entire study cohort.
The most commonly observed toxicity was urinary frequency.
At 1 month, grades 1–2 urinary frequency were reported by 32.3%
of patients with a rate of 19.6% observed at 6 months and subse-
quent declines thereafter. Two patients experienced grade 3 urinary
frequency (frequency greater than every hour) during treatment
but did not require catheterization. Grades 1–2 urinary dysuria
and retention were reported by 16.6 and 7.8% of patients at
1 month and 2.9 and 4.9% at 6 months, respectively. No grade
3 or greater dysuria or retention was observed. Rectal toxicity
was uncommon. At 6 months, two patients reported grade 1 rec-
tal bleeding, and additional patient reported grade 1 bleeding at
12 months. All three patients experienced resolution of their bleed-
ing without intervention. No patient experienced any grade 3 or
greater rectal toxicity at any post-SABR follow-up point.
Mean PSA measurement for the entire study cohort demon-
strated a rapid decline over the first 12 months of follow-up.
Biochemical response as a function of post-treatment time is rep-
resented graphically in Figure 3. Fifteen patients (14.7%) demon-
strated a PSA “bounce” between 12 and 24 months post-SABR,
accounting for the sustained elevation observed in the maximum
PSA curve. No biochemical failures were noted by 5 years follow-
up, although one patient has demonstrated biochemical failure at
6 years.
Quality of life results are presented in Table 2. The EPIC
domains studied include urinary incontinence, urinary irritation
or obstruction, rectal function, and sexual function. Declines in all
domains were observed at 1 month post-treatment, but only uri-
nary irritation/obstruction declined significantly. By 12 months,
EPIC domain scores were observed to return to near-baseline
levels. By 60 months, scores were observed to decline nomi-
nally for all domains but not significantly versus pre-treatment
scores.
DISCUSSION
Published clinical evidence generally supports the safety and effi-
cacy of hypofractionation for low-risk prostate cancer. However,
many reported studies have included patients across multiple dis-
ease risk groups and have variably used androgen deprivation
therapy, creating challenges in the interpretation of their find-
ings. Kupelian et al. conducted a phase II trial of external beam
radiotherapy delivering 70.0 Gy in 2.5-Gy daily fractions at Cleve-
land Clinic and reported late grade 3 rectal and urinary toxicities
at 5 years of 3 and 1%, respectively, and>90% biochemical disease
control at 5 years for low- and intermediate-risk disease patients,
some of whom also received androgen suppression therapy (24,
25). RTOG 0415 subsequently randomized low-risk (clinical stage
T1-2, PSA <10 ng/ml and Gleason score ≤6) patients either to
the Cleveland Clinic hypofractionation scheme or to conventional
fractionation (73.8 Gy in 1.8-Gy daily fractions). Patients in either
study arm received no hormonal therapy. Published results from
this trial are pending.
Other randomized studies of patients in multiple risk cate-
gories and treated variably with hormonal therapy have compared
hypofractionated treatment schedules to dose-escalated, conven-
tionally fractionated external beam therapy and have generally
reported disease control and toxicity equivalence between the two
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Table 1 | National Cancer Institute common terminology criteria for adverse events, version 3.0 for (A) urinary and (B) rectal toxicities.
Adverse event Grade
1 2 3 4 5
(A) URINARYTOXICITIES
Dysuria/hematuria Asymptomatic Frequency with dysuria;
macroscopic hematuria
Transfusion; IV pain
medications; bladder irrigation
indicated
Catastrophic bleeding;
major non-elective
intervention indicated
Death
Incontinence Occasional; pads not
indicated
Spontaneous, pads
indicated
Intervention indicated Operative intervention
indicated
–
Stricture/stenosis Asymptomatic,
radiographic or
endoscopic findings only
Symptomatic but no
hydronephrosis, sepsis or
renal dysfunction; dilation
or endoscopic repair or
stent placement indicated
Symptomatic and altered organ
function; operative intervention
indicated
Life-threatening
consequences; organ
failure or operative
intervention requiring
organ resection indicated
Death
Urinary fre-
quency/urgency
Increase in frequency or
nocturia up to 2× normal;
enuresis
Increase >2× normal but
<hourly
≥1×/h; urgency; catheter
indicated
– –
Urinary obstruc-
tion/retention
Hesitancy or dribbling, no
significant residual urine;
retention occurring
during the immediate
postoperative period
Hesitancy requiring
medication; or operative
bladder atony requiring
indwelling catheter for
<6 weeks
More than daily catheterization
indicated; urological
intervention indicated
Life-threatening
consequences; organ
failure; operative
intervention requiring
organ resection indicated
Death
(B) RECTALTOXICITIES
Diarrhea Increase of <4 stools per
day over baseline; mild
increase in ostomy
output compared to
baseline
Increase of 4–6 stools per
day over baseline; IV fluids
indicated <24 hrs;
moderate increase in
ostomy output compared
to baseline
Increase of ≥7 stools per day
over baseline; incontinence; IV
fluids ≥24 hrs; hospitalization;
severe increase in ostomy
output compared to baseline
Life-threatening
consequences
Death
Hematochezia Asymptomatic Symptomatic; banding or
medical intervention
indicated
Interventional radiology,
endoscopic, or operative
intervention indicated
Life-threatening
consequences
Death
Incontinence Occasional use of pads
required
Daily use of pads required Interfering with ADL; operative
intervention indicated
Permanent bowel
diversion indicated
Death
Proctitis Rectal discomfort,
intervention not indicated
Medical intervention
indicated
Stool incontinence; operative
intervention indicated
Life-threatening
consequences
Death
fractionation strategies. The conventional versus hypofractionated
high-dose intensity-modulated radiotherapy for prostate cancer
(CHHiP) trial enrolled 444 patients with Gleason score ≤7 dis-
ease to conventionally fractionated (74 Gy in 2.0-Gy fractions)
or hypofractionated (57–60 Gy in 3.0-Gy fractions) radiotherapy
(26). No statistically significant differences in urinary or rectal
toxicities have been observed between the two arms. An Italian ran-
domized study of 168 high-risk disease patients reported similar
late toxicities between its two arms of conventional hypofrac-
tionated radiotherapy and statistically significant improvement of
biochemical disease control at 3 years for hypofractionated ther-
apy (27). Pollack et al. reported the results of a randomized study
of 303 patients with low-to-high-risk localized disease treated
with either 76.0 Gy in 2.0-Gy fractions or 70.2 Gy in 2.7-Gy frac-
tions. While disease control outcomes were similar between the
two arms, urinary toxicity among patients with AUA scores >10
at baseline was significantly greater for hypofractionated ther-
apy. Otherwise, late toxicities were found to be similar between
the two groups (28). M. D. Anderson reported early results of
a randomized trial comparing more moderate hypofractionation
(72.0 Gy in 2.4-Gy fractions) to conventionally fractionated ther-
apy among 203 patients with low- and intermediate-risk disease. A
non-significant trend for increased late rectal toxicity was discov-
ered among hypofractionated patients, particularly for treatment
plans demonstrating high doses delivered to >20% of the rectal
volume (29).
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Several single-institution published prospective studies of
SABR fractionation for prostate cancer have generally estab-
lished the feasibility of delivering very large fraction sizes safely
and effectively using modern linac platforms, predominantly the
CyberKnife system (30–35). These studies employed treatment
schedules of 6.7–10 Gy fractions to total doses of 33.5–50.0 Gy
over five fractions. A pooled analysis of published and previously
unpublished data was recently reported by King et al. and con-
sisted of 1100 low-to-high-risk disease patients largely treated to a
total dose of 36.25 Gy using the CyberKnife system. Some patients
also received androgen suppression. For 135 patients with mini-
mum 5-year follow-up, biochemical relapse-free survival was 99
and 93% for low- and intermediate-risk patients, respectively (36).
Quality of life outcomes were reported in a separate report by the
same group. With 194 patients evaluable at 5 years and using EPIC
methodology, declines in urinary and bowel domain scores were
observed within the first 3 months post-treatment followed by a
return to baseline after 6 months post-treatment. Sexual domain
scores were found to have declined predominantly over the first
9 months post-treatment (37). At present, several clinical trials
are comparing stereotactic radiotherapy to other fractionation
schemes: RTOG 0938 has randomized favorable risk patients to
36.25 Gy in five fractions versus 51.6 Gy in 12 fractions; the PACE
trial (prostate advanced in comparative evidence) has randomized
FIGURE 3 | PSA as a function of post-treatment time.
low- and intermediate-risk patients to 36.25 Gy in five fractions
or 38.0 Gy in four fractions versus laparoscopic prostatectomy or
conventionally fractionation radiotherapy; and the HYPO-RT-PC
trial (hypofractionated radiotherapy of intermediate-risk local-
ized prostate cancer) is randomizing patients between 42.7 Gy in 7
fractions versus 78.0 Gy in 39 fractions. Results from these studies
are pending.
Complementing the pooled analyses of the CyberKnife expe-
rience discussed above, this report provides long-term disease
control, toxicity, and quality of life outcomes for a patient cohort
treated with a modern, non-robotic linear accelerator at a sin-
gle institution. Broad comparisons of these outcomes between
the two reports suggest therapeutic equivalence between the two
technology platforms in delivering SABR for localized prostate
cancer. Some of the key technical differences between the two
platforms merit mention. The SABR platform in this study allows
for real-time target tracking with an integrated Calypso® System
and is therefore distinguished from the CyberKnife, which instead
employs an orthogonal planar x-ray imaging system to obtain
non-continuous, three-dimensional positional data of implanted
fiducial markers at defined time points during treatment delivery.
The Calypso® System generates an electromagnetic field within
the patient to oscillate implanted beacon transponders. When the
field is turned off, the transponders emit a signal that is received
by the system to determine their positions within the prostate.
This function is performed 10 times per second to provide real-
time target tracking. There is no use of x-rays and therefore
no added radiation exposure for the patient. At the time this
study was designed, we believed that real-time tracking offered
a more complete solution to the problem of intrafractional pro-
static displacements than did punctuated imaging – particularly
when very large and few treatment fractions are prescribed as in
SABR – and would confidently permit the use of very narrow
treatment margins in order to optimize the therapeutic ratio from
a geometric perspective. Pre-study testing with beacon-implanted,
non-protocol patients supported the selection of the 2-mm action
threshold as an acceptable compromise between system sensitiv-
ity for triggering a corrective action and throughput efficiency.
Of the 510 total SABR fractions delivered to the 102 patients
reported here, the 2-mm threshold was observed to be breached
at least once during 132 fractions (25.8%), and excursions of
>2 mm for>2 min requiring patient and target realignment were
observed during 26 fractions (5.1%). Among all treatment frac-
tions, the average time observed between beam-on and beam-off
was 14.2 min.
Table 2 | Pre- and post-treatment EPIC scores.
EPIC domain Mean EPIC score (SD) Clinically significant decline (>0.5 SD)
Pre-SABR Post-SABR at
1 month
Post-SABR at
12 months
Post-SABR at
60 months
At 1 month At 12 months At 60 months
Bowel/rectal 92.1 (19.7) 84.4 (17.7) 91.4 (15.1) 91.0 (14.8) No No No
Urinary irritation/obstruction 85.4 (18.3) 74.9 (20.6) 83.2 (16.7) 81 1 (18 9) Yes No No
Urinary incontinence 94.0 (11.9) 90.3 (21.3) 93.1 (16.9) 92 2 (16 7) No No No
Sexual function 51.4 (32.9) 51.3 (25.9) 51.0 (26.0) 47.9 (29.2) No No No
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CONCLUSION
Favorable 5-year results of this phase II trial support the use of
non-robotic, real-time target tracking SABR for low-risk prostate
cancer.
REFERENCES
1. Available from: https://www.astro.org/uploadedFiles/Main_Site/Practice_
Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf
2. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate
carcinoma. Int J RadiatOncol Biol Phys (1999) 43:1095–101. doi:10.1016/S0360-
3016(98)00438-6
3. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour
EP. Direct evidence that prostate tumors show high sensitivity to fractionation
(low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol
Phys (2002) 52:6–13. doi:10.1016/S0360-3016(01)02664-5
4. Wang JZ, Guerrero M, Allen LX. How low is the α/β ratio for prostate cancer?
Int J Radiat Oncol Biol Phys (2003) 55:194–203. doi:10.1016/S0360-3016(02)
03828-2
5. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated proto-
cols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys (2003)
56:1093–104. doi:10.1016/S0360-3016(03)00132-9
6. King CR, Fowler JF. A simple analytic derivation suggests that prostate alpha/beta
ratio is low. Int J Radiat Oncol Biol Phys (2001) 51:213–4. doi:10.1016/S0360-
3016(01)01651-0
7. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low? Int J Radiat
Oncol Biol Phys (2001) 50:1021–31. doi:10.1016/S0360-3016(01)01607-8
8. Brenner DJ. Toward optimal external-beam fractionation for prostate cancer. Int
J Radiat Oncol Biol Phys (2000) 48:315–6. doi:10.1016/S0360-3016(00)00591-5
9. Duschesne GM, Peters LJ. What is the α/β ratio for prostate cancer? Rationale
for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys
(1999) 44:747–8.
10. Ritter M. Rationale, conduct, and outcome using hypofractionated radiother-
apy in prostate cancer. Semin Radiat Oncol (2008) 18:249–56. doi:10.1016/j.
semradonc.2008.04.007
11. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropri-
ate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol
(2008) 18:240–3. doi:10.1016/j.semradonc.2008.04.005
12. Park C, Papiez S, Zhang M, Story M, Timmerman RD. Universal survival curve
and single fraction equivalent dose: useful tools in understanding potency
of ablative radiotherapy. Int J Radiat Oncol Biol Phys (2008) 70:847–52.
doi:10.1016/j.ijrobp.2007.10.059
13. Byrne TE. A review of prostate motion with considerations for the treatment
of prostate cancer. Med Dosim (2005) 30:155–61. doi:10.1016/j.meddos.2005.
03.005
14. Kitamura K, Shirato H, Seppenwoolde Y, Onimaru R, Oda M, Fujita K, et al.
Three-dimensional intrafractional movement of prostate measured during real-
time tumor-tracking radiotherapy in supine and prone treatment positions.
Int J Radiat Oncol Biol Phys (2002) 53:1117–23. doi:10.1016/S0360-3016(02)
02882-1
15. Britton KR, Takai Y, Mitsuya M, Nemoto K, Ogawa Y, Yamada S. Evaluation
of inter- and intrafraction organ motion during intensity modulated radiation
therapy (IMRT) for localized prostate cancer measured by a newly developed
on-board image-guided system. Radiat Med (2005) 23:14–24.
16. Huang E, Dong L, Chandra A, Kuban DA, Rosen II, Evans A, et al. Intrafraction
prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys
(2002) 53:261–8. doi:10.1016/S0360-3016(02)02738-4
17. Nederveen AJ, van derHeide UA, Dehnad H, van Moorselaar RJ, Hofman P,
Lagendijk JJ. Measurements and clinical consequences of prostate motion dur-
ing a radiotherapy fraction. Int J Radiat Oncol Biol Phys (2002) 53:206–14.
doi:10.1016/S0360-3016(01)02823-1
18. Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, et al. Simulated real
time image guided intrafraction tracking-delivery for hypofractionated prostate
IMRT. Med Phys (2008) 35:4041–8. doi:10.1118/1.2968333
19. Boike T, Anderson J, Novotny J, Abdulrahman R, Pistenmaa D, Timmerman R.
Intra-fraction and inter-fraction prostate motion associated with stereotactic
body radiation therapy (SBRT) and image guided radiation therapy (IGRT). Int
J Radiat Oncol Biol Phys (2007) 69:S355. doi:10.1016/j.ijrobp.2007.07.1446
20. Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S, et al.
Multi-institutional clinical experience with the Calypso System in localization
and continuous, real-time monitoring of the prostate gland during external
radiotherapy. Int J Radiat Oncol Biol Phys (2007) 67:1088–98. doi:10.1016/j.
ijrobp.2006.10.026
21. Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K,
et al. Reduction in acute morbidity using hypofractionated intensity-modulated
radiation therapy assisted with a fluoroscopic real-time tumor tracking system
for prostate cancer: Preliminary results of a phase I/II study. Cancer J (2003)
9:268–76. doi:10.1097/00130404-200307000-00009
22. Cheung P, Sixel K, Morton G, Loblaw DA, Tirona R, Pang G, et al. Individual-
ized planning target volumes for intrafraction motion during hypofractionated
intensity-modulated radiotherapy boost for prostate cancer. Int J Radiat Oncol
Biol Phys (2005) 62:418–25. doi:10.1016/j.ijrobp.2004.09.051
23. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al.
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and
biochemical outcomes. Lancet Oncol (2012) 13:43–54. doi:10.1016/j.ijrobp.
2007.10.004
24. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A.
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per frac-
tion) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol
Phys (2005) 63:1463–8. doi:10.1016/j.ijrobp.2005.05.054
25. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofrac-
tionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for
localized prostate cancer: the Cleveland Clinic experience. Int J Radiat Oncol
Biol Phys (2007) 68:1424–30. doi:10.1016/j.ijrobp.2007.01.067
26. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Con-
ventional versus hypofractionated high-dose intensity-modulated radiotherapy
for prostate cancer: preliminary safety results from the CHHiP randomized
controlled trial. Lancet Oncol (2012) 13:43–54. doi:10.1016/S1470-2045(11)
70293-5
27. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S,
et al. A prospective phase III randomized trial of hypofractionated versus con-
ventional fractionation in patients with high-risk prostate cancer. Int J Radiat
Oncol Biol Phys (2010) 78:11–8. doi:10.1016/j.ijrobp.2009.07.1691
28. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Ran-
domized trial of hypofractionated external-beam radiotherapy for prostate can-
cer. J Clin Oncol (2013) 31:1–11. doi:10.1200/JCO.2013.51.1972
29. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, et al. Risk of late
toxicity in men receiving dose-escalated hypofractionated intensity modulated
prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol
Biol Phys (2014) 88:1074–84. doi:10.1016/j.ijrobp.2014.01.015
30. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiother-
apy for organ-confined prostate cancer. BMC Urol (2010) 10:1. doi:10.1186/
1471-2490-10-1
31. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic
hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in 5
fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol
Phys (2007) 67:1099–105. doi:10.1016/j.ijrobp.2006.10.050
32. Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, et al. Phase I/II
study of a five-fraction hypofractionated accelerated radiotherapy treatment for
low-risk prostate cancer: early results of pHART3. Clin Oncol (2008) 20:729–37.
doi:10.1016/j.clon.2008.08.006
33. King CR, Brooks JD, Gill H, Presti JCJr. Long term outcomes from a prostatecive
trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat
Oncol Biol Phys (2012) 82:877–82. doi:10.1016/j.ijrobp.2010.11.054
34. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN,
et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate ade-
nocarcinoma: preliminary results of a multi-instituional phase I feasibility trial.
Cancer (2012) 118:3681–90. doi:10.1002/cncr.26699
35. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, et al. Phase I
dose-escalation study of stereotactic body radiation therapy for low- and
intermediate-risk prostate cancer. J Clin Oncol (2011) 29:2020–6. doi:10.1200/
JCO.2010.31.4377
36. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic
body radiotherapy for localized prostate cancer: pooled analysis from a multi-
institutional consortium of prospective phase II trials. Radiother Oncol (2013)
109:217–21. doi:10.1016/j.radonc.2013.08.030
www.frontiersin.org November 2014 | Volume 4 | Article 279 | 7
Mantz Prostate cancer linac-based SBRT
37. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-
related quality of life after stereotactic body radiation therapy for localized
prostate cancer: results from a multi-institutional consortium of prospective
trials. Int J Radiat Oncol Biol Phys (2013) 87:939–45. doi:10.1016/j.ijrobp.2013.
08.019
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 26 August 2014; paper pending published: 11 September 2014; accepted: 27
September 2014; published online: 14 November 2014.
Citation: Mantz C (2014) A phase II trial of stereotactic ablative body radiotherapy
for low-risk prostate cancer using a non-robotic linear accelerator and real-time target
tracking: report of toxicity, quality of life, and disease control outcomes with 5-year
minimum follow-up. Front. Oncol. 4:279. doi: 10.3389/fonc.2014.00279
This article was submitted to Radiation Oncology, a section of the journal Frontiers in
Oncology.
Copyright © 2014 Mantz. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Oncology | Radiation Oncology November 2014 | Volume 4 | Article 279 | 8
